

Document Detail

Type: PMF IBTS SPEC

Document No.: IBTS/PMF/SPEC/0208[6]

Title: WHOLE BLOOD, SUITABLE FOR NEONATAL USE FOR 5

DAYS AFTER DATE DRAWN

Owner: QA DOC CON QA DOC CONTROL

Status CURRENT **Effective Date:** 19-May-2025 **Expiration Date:** 19-May-2027

Review

Review: IBTS PMF REVIEW

Level	Owner Role	Actor	Sign-off By
1	DOCUMENT CONTROLLER	BECKY WHITE	BECKY WHITE
2	SSCD WRITER IBTS	LIAM MORGAN	LIAM MORGAN
3	COMPONENTS HEAD OF DEPT MRTC	AINE FITZPATRICK	AINE FITZPATRICK
3	LABS PHS DIR IBTS	BARRY DOYLE	BARRY DOYLE
3	MEDICAL & SCIENTIFIC DIRECTOR	ANDREW GODFREY	ANDREW GODFREY
3	SSCD HEAD OF DEPT IBTS	AILEEN FARRELLY	AILEEN FARRELLY
4	QUALITY ASSURANCE REVIEWER IBTS	COLIN JOHNS	COLIN JOHNS

Change Orders

Changes as described on Change Order: <u>Change Order No.</u>

Change Orders - Incorporated

Changes as described on Change Order: Change Order No.

IBTS/CO/0219/25

IRISH BLOOD TRANSFUSION SERVICE PRODUCT MASTER FILE

TITLE: WHOLE BLOOD, SUITABLE FOR NEONATAL USE FOR 5 DAYS

AFTER DATE DRAWN

Change Description:

Revise the Labelling and Barcode Illustrations.

Reason for Change:

To update the PMFs with new Label Versions (Ref CC 208/23 & 002/24)

Change order No.:

IBTS/CO/0219/25

Referenced Documents

N/A

SmartSolve Roles

N/A

Training Type

N/A

SmartSolve Document Category

Category	Mobile	Cryobiology	Website	GDP
Yes / No	No	No	Yes	No

IBTS/PMF/SPEC/0208	Ver. 6	Page 3 of 10
1516,1111,6126,6266	7 6.1. 6	. 480 0 0. 20

IRISH BLOOD TRANSFUSION SERVICE

PRODUCT MASTER FILE

Title: Whole Blood, Suitable for Neonatal Use for 5 Days after Date Drawn

Name of Products:

- WHOLE BLOOD, Suitable for Neonatal Use for 5 days after Date Drawn. HCT Range: 0.50 -0.60
- WHOLE BLOOD, Suitable for Neonatal Use, Irradiated HCT Range: 0.50 0.60
 And
- WHOLE BLOOD, Suitable for Neonatal Use for 5 days after Date Drawn. HCT Range: 0.50

 -0.55
- WHOLE BLOOD, Suitable for Neonatal Use, Irradiated HCT Range: 0.50 0.55

E Progesa Codabar Component Codes:

54350 / 39360 and 39361 / 39362

E Progesa ISBT -128 Component Codes:

E8215V00 / E8212V00 and E8217V00 / E8216V00

General Description: Plasma reduced whole blood obtained from: WHOLE BLOOD, Suitable for Neonatal Use for 5 days after Date Drawn

10

WHOLE BLOOD, Reconstituted, Suitable for Neonatal Use obtained by centrifugation and removal of part of the plasma or additive solution, respectively.

General Specification:

Parameter	Quality Requirement	Frequency of Control
Volume	volume monitored by SPC	100%
Haematocrit	0.50 - 0.60 L/L 0.50 - 0.55 L/L	100 %
Haemoglobin	≥ 40 g/unit	≥1%
Leucocyte Content	< 1 x 10 ⁶ /unit	≥1%
Haemolysis at end of shelf life	< 0.8% of red cell mass	4 per annum (including irradiated)
ABO Agglutinins	No HighTitre Anti-A or Anti-B	100%
CMV	CMV ab negative	100%

IBTS/PMF/SPEC/0208	Ver. 6	Page 4 of 10
IBTS/PMF/SPEC/0208	Ver. 6	Page 4 of 10

Labelling: See Appendix I and II

Storage: Whole Blood, Suitable for Neonatal Use for 5 days after date drawn /

Whole Blood, Suitable for Neonatal Use, Irradiated (with Hct. ranges of

0.50-0.60 L/L or 0.50-0.55 L/L,) should be stored at 4° C \pm 2° C.

For exchange or massive transfusion of neonates it should be used within 5 days after date drawn and up to 24 hrs after irradiation. For adult use it

can be stored up to 28 days.

Irradiation: Whole Blood, Suitable for Neonatal Use for 5 days after date drawn for

exchange should be irradiated before transfusion provided this does not unduly delay the transfusion. Post irradiation the product should be used within 24 hours. It **must** be irradiated prior to transfusion where the neonate has had a previous intrauterine transfusion. If irradiated, the

component codes will change to 39360/E8212V00 and 39362/E8216V00.

Transportation: The air temperature of transport containers for units of Whole Blood, Suitable for Neonatal Use for 5 days after date drawn / Whole Blood, Suitable for Neonatal Use, Irradiated (with Hct. ranges of 0.50-0.60 L/L or 0.50-0.55 L/L,) should be maintained between 2°C and 10°C during

transport from the Irish Blood Transfusion Service to the place where they are intended for use. Transport time under these conditions

normally should not exceed 8 hours.

Indications for Use: Whole Blood, Suitable for Neonatal Use for 5 days after date drawn / Whole Blood, Suitable for Neonatal Use, Irradiated (with Hct. ranges of 0.50-0.60 L/L or 0.50-0.55 L/L,) are used to augment the oxygen delivery capacity of the blood where this is critically impaired. Typically indicated for:

- Exchange transfusion of neonates.

- Massive transfusion in neonates and small infants.
- adult transfusion.

Precautions in Use:

- Compatibility of this component with the intended recipient must be verified by suitable pre transfusion testing.
- Whole Blood, Suitable for Neonatal Use for 5 days after date drawn / Whole Blood, Suitable for Neonatal Use, Irradiated (with Hct. ranges of 0.50-0.60 L/L or 0.50-0.55 L/L,) should be transfused through a standard 170 – 200 µm filter.
- No solution should be added to the bag or to the giving set.
- Components should be inspected visually for defects, leakage, abnormal colour or visible clots.
- Whole Blood, Suitable for Neonatal Use for 5 days after date drawn / Whole Blood, Suitable for Neonatal Use, Irradiated (with Hct. ranges of 0.50-0.60 L/L or 0.50-0.55 L/L,) are not recommended in:
 - various types of plasma intolerance.
 - repeated leucocyte antigen/antibody mediated reaction unresponsive to medication

IBTS/PMF/SPEC/0208	Ver. 6	Page 5 of 10
--------------------	--------	--------------

Adverse Effects Include:

- Circulatory Overload.
- Haemolytic transfusion reaction;
- Non-haemolytic transfusion reaction (mainly chills, fever and urticaria).

The risk is reduced by leucodepletion and washing

Pathogen transmission

- Despite careful donor selection and laboratory screening procedures, infections including Syphilis, Viral Hepatitis, HIV, HTLV 1 & 11 and other viruses and protozoa (e.g. malaria) may, in rare instances, occur.
- vCJD transmission
- Transmission of other pathogens that are not tested for or recognised.
- The risk of CMV transmission is minimal as the components are leucodepleted
- Sepsis due to bacterial contamination (reduced but not eliminated by bacterial screening)

Metabolic upset

- Possible elevated potassium level in massive transfusions, especially where patient is hypothermic or acidotic or has impaired renal function.
- Citrate toxicity, especially in neonates and in patients with impaired hepatic function.
- Hypocalcaemia.
- Hypoglycaemia.
- Hypokalaemia.

Immunological effects

- Alloimunisation to HLA and red cell antigens.
- Graft vs Host Disease (GvHD) in immuno compromised recipients . The risk of GvHD is eliminated by irradiation
- Transfusion related Acute Lung injury (TRALI) by donor HLA/granulocyte antibodies.
- Post transfusion purpura (PTP).

• Iron overload

- In patients on chronic red cell transfusion support programmes.

Serious Adverse Reaction

Please inform the IBTS immediately about any event relating to suspected bacterial sepsis/ transfusion associated bacterial sepsis

Serious adverse reactions should be reported to:

National Haemovigilance Office

Irish Blood Transfusion Service National Blood Centre James's Street Dublin 8

AND

Quality Assurance Manager

Irish Blood Transfusion Service

AT EITHER

National Blood Centre James's Street Dublin 8

<u>OR</u>

Munster Regional Transfusion Centre
St Finbarr's Hospital
Douglas Road, Cork

APPENDIX I

E Progesa Codabar Component Code:

54350

E Progesa ISBT – 128 Component Code:

E8215V00

Product Name

WHOLE BLOOD, Suitable for Neonatal Use for 5 Days after Date Drawn. HCT Range: 0.50 - 0.60

Shelf life

28 days

Labelling and Barcode:

(for illustration purposes only - barcodes not suitable for scanning - label not to scale)



Υer

WHOLE BLOOD, Suitable for Neonatal Use for 5 days after Date Drawn. HCT Range: 0.50-0.60

Store at 4°C ± 2°C



Drawn 09 May 2025



Negative

Confirmed Group CMV Antibody Negative



E8215V00

This component must not be used if there are visible signs of deterioration. This component may transmit infection

Must be administered using a suitable transfusion set incorporating a 170 - 200 µm filter. Collected into 66ml of CPD anticoagulant containing, in

Citric Acid 16, Sodium Citrate 89, Sodium Dihydrogen Phosphate 16, Total Na Concentration 284.






Expiry 06 June 2025 23:59



93999999999917796

C-E-c+e+K-HbS-Neg







APPENDIX 1

E Progesa Codabar Component Code: 39360

E Progesa ISBT – 128 Component Code: E8212V00

Product Name

WHOLE BLOOD, Suitable for Neonatal Use, Irradiated. HCT Range: 0.50 - 0.60

Shelf life

24 hours

Labelling and Barcode:

iffective 19 May (for illustration purposes only - barcodes not suitable for scanning - label not to scale)



ST8 ٧er

WHOLE BLOOD, Suitable for Neonatal Use, Irradiated. HCT Range: 0.50-0.60

Store at $4^{\circ}C \pm 2^{\circ}C$



Drawn 09 May 2025



E8212V00

This component must not be used if there are visible signs of deterioration. This component may transmit infection Must be administered using a suitable transfusion set incorporating a 170 – 200 µm filter. Collected into 66ml of CPD anticoagulant containing, in Citric Acid 16. Sodium Citrate 89, Sodium Dihydrogen Phosphate 16, Glucose 129, Total Na Concentration 284.



Rh D Positive

CMV Antibody Negative IRRADIATED (24 H) Confirmed Group

300

Expiry 10 May 2025 15:37



93999999999918496

C- E+ c+ e- K- HbS-Neg



Expiry 10/05/2025



APPENDIX II

E Progesa Codabar Component Code: 39361

E Progesa ISBT – 128 Component Code:

Product Name

WHOLE BLOOD, Suitable for Neonatal Use for 5 Days after Date Drawn. HCT Range: 0.50 – 0.55


Labelling and Barcode:

Shelf life 28 days (for illustration purposes only - barcodes not suitable for scanning - label not to scale)



WHOLE BLOOD, Suitable for Neonatal Use for 5 days after Date Drawn. HCT Range: 0.50-0.55

Store at $4^{\circ}C \pm 2^{\circ}C$



300



Confirmed Group CMV Antibody Negative

Expiry 06 June 2025 23:59



E8217V00

This component must not be used if there are visible signs of deterioration. This component may transmit infection

Must be administered using a suitable transfusion set incorporating a 170 - 200 µm filter. Collected into 66ml of CPD anticoagulant containing, in mmol/l:

Citric Acid 16, Sodium Citrate 89, Sodium Dihydrogen Phosphate 16, Glucose 129, Total Na Concentration 284.



Expiry 06/06/2025

939999999199917796 C- E- c+ e+ K- Jkb- HbS-Neg

0251572359

APPENDIX II

E Progesa Codabar Component Code: 39362

E Progesa ISBT – 128 Component Code: E8216V00

Product Name

24 hours WHOLE BLOOD, Suitable for Neonatal Use, the time 19 Ma

Irradiated.

HCT Range: 0.50 - 0.55

Labelling and Barcode:

(for illustration purposes only - barcodes not suitable for scanning - label not to scale)



IBTS ver 4.0

Shelf life

WHOLE BLOOD, Suitable for Neonatal Use, Irradiated

HCT Range: 0.50 - 0.55 Store at $4^{\circ}C \pm 2^{\circ}C$



Drawn 09 May 2025



E8216V00

This component must not be used if there are visible signs of deterioration. This component may transmit infection Must be administered using a suitable transfusion set incorporating a 170 - 200 µm filter. Collected into 66ml of CPD anticoagulant containing, in mmol/l:

Citric Acid 16, Sodium Citrate 89, Sodium Dihydrogen Phosphate 16,



39362



Rh D Positive

CMV Antibody Negative IRRADIATED (24 H) **Confirmed Group**



Expiry 10 May 2025 15:39



939959999999924796

C+ E- c- e+ S- s+ K- HbS-Neg



Expiry 10/05/2025

